Anas Alshawa

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Takeo Fujii, Rivka R. Colen, Mehmet Asım Bilen et al. · Investigational New Drugs · 2017 · 183 citations · Full text

Medicine, Immunology, Oncology +16

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Aung Naing, Funda Meric‐Bernstam, Bettzy Stephen et al. · Journal for ImmunoTherapy of Cancer · 2020 · 131 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept

Rivka R. Colen, Takeo Fujii, Mehmet Asım Bilen et al. · Investigational New Drugs · 2017 · 120 citations · Full text

Medicine, Immunology, Internal Medicine +12

Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study

Nazanin Majd, Steven G. Waguespack, Filip Jankú et al. · Journal for ImmunoTherapy of Cancer · 2020 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Anne Knisely, Jibran Ahmed, Bettzy Stephen et al. · Cancer · 2023 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17